×

US FDA declines to approve Capricor’s cell therapy for Duchenne muscular dystrophy; shares slump

By Thomson Reuters Nov 20, 2026 | 5:44 PM

Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics’ experimental cell therapy for a fatal ​inherited disease that weakens muscle, the ‌health regulator said on Friday, adding to a string of regulatory setbacks for the biotech firm.

Shares of the company were down 72% in extended trading.

Capricor ‌was ​seeking approval for the ⁠therapy, known as deramiocel, ⁠to preserve upper-limb function in Duchenne muscular dystrophy patients.

The agency said serious data integrity problems in a key clinical trial meant ​the evidence did not meet the standard for approval.

Duchenne is a fatal genetic ⁠disease that primarily affects boys ⁠and causes progressive muscle weakness, ​loss of mobility, heart complications and premature death.

The ​regulatory rejection deals a heavy blow to ‌Capricor, threatening its lead experimental asset and clouding the company’s commercial prospects after months of efforts to salvage the application by narrowing ⁠its focus to arm and hand movement.

The decision follows a nine-to-three vote in July in which ⁠the FDA’s ‌advisers said the evidence presented at ⁠the time did not establish ​deramiocel’s ‌effectiveness in Duchenne-related heart disease. Capricor ​subsequently amended ⁠its application with new data supporting a refined proposed indication focused on upper limb function.

(Reporting by Kunal Das, Sahil Pandey and Kamal Choudhury in Bengaluru. Editing by Alan Barona and ​Perla Velasco)